• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Intensive Care Med . Multi-inflammatory Index as a Novel Mortality Predictor in Critically Ill COVID-19 Patients

tetano

Editor, Senior Moderator
J Intensive Care Med


. 2022 May 11;8850666221100411.
doi: 10.1177/08850666221100411. Online ahead of print.
Multi-inflammatory Index as a Novel Mortality Predictor in Critically Ill COVID-19 Patients


Hasan Tahsin Gozdas[SUP] 1 [/SUP], Seyit Ali Kayis[SUP] 2 [/SUP], Tugce Damarsoy[SUP] 1 [/SUP], Emine Ozsari[SUP] 3 [/SUP], Mustafa Turkoglu[SUP] 4 [/SUP], Isa Yildiz[SUP] 5 [/SUP], Abdullah Demirhan[SUP] 5 [/SUP]



Affiliations

Abstract

Aim: Systemic inflammation has a crucial role in the pathogenesis and mortality of Coronavirus disease 2019 (COVID-19). Multi-inflammatory index (MII) is a novel index related with systemic inflammation. In this study, we investigated the relationship between MII and in-hospital mortality in COVID-19 patients admitted to the intensive care unit (ICU).
Methods: We retrospectively analyzed the medical records of COVID-19 patients followed-up in the ICU of our institution between 01.04.2020 and 01.10.2021. Patients were classified into two groups according to mortality status as survivors and non-survivors. Various inflammatory parameters of the groups were compared and their efficacy in predicting mortality was investigated.
Results: Out of 348 study patients, 86 cases (24.7%) were in the survived group and 262 cases (75.3%) were in the dead group. The median age of the mortal group was significantly higher than that of the survived group (65.5 vs 76, P < .001). Multiple logistic regression analysis revealed that among all the included inflammatory parameters, MII showed the best efficacy for predicting mortality (OR: 0.999; 95% CI: 0.9991-0.9998; P = .003).
Conclusion: MII, a new combination of Neutrophil to lymphocyte ratio (NLR) and C-reactive protein (CRP), is a simple and practical biomarker that can help us in the prediction of mortality in COVID-19 patients followed-up in the ICU.

Keywords: coronavirus disease 2019; intensive care unit; mortality; multi-inflammatory index.
 
Back
Top Bottom